- $1.32bn
 - $931.80m
 - $682.16m
 
- 61
 - 81
 - 72
 - 83
 
Annual balance sheet for Novavax, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st  | 2021 December 31st  | 2022 December 31st  | 2023 December 31st  | 2024 December 31st  | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — | 
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K | 
| Standards: | USG | USG | USG | USG | USG | 
| Status: | Final | Final | Final | Final | Final | 
| Cash | |||||
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 711 | 1,515 | 1,337 | 569 | 923 | 
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 262 | 455 | 82.4 | 297 | 108 | 
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 1,248 | 2,155 | 1,703 | 1,144 | 1,129 | 
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 188 | 269 | 400 | 491 | 300 | 
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Other Long Term Assets | |||||
| Total Assets | 1,582 | 2,577 | 2,259 | 1,797 | 1,560 | 
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 580 | 2,390 | 2,460 | 1,635 | 1,154 | 
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 955 | 2,928 | 2,893 | 2,514 | 2,184 | 
| Non Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Other Equity | |||||
| Total Equity | 627 | -352 | -634 | -717 | -624 | 
| Total Liabilities & Shareholders' Equity | 1,582 | 2,577 | 2,259 | 1,797 | 1,560 | 
| Total Common Shares Outstanding |